Prevalence of HIV Drug Resistance Mutations in HIV Type 1 Isolates in Antiretroviral Therapy Naïve Population from Northern India by Sinha, S. et al.
Hindawi Publishing Corporation
AIDS Research and Treatment
Volume 2012, Article ID 905823, 6 pages
doi:10.1155/2012/905823
Research Article
Prevalence of HIV Drug Resistance Mutations in
HIVType1IsolatesinAntiretroviral
Therapy Na¨ ıve Population from Northern India
S. Sinha,1 H. Ahmad,2 R. C. Shekhar,1 N. Kumar,1 L. Dar,2 J. C. Samantaray,2 S. K. Sharma,1
A.Bhargava,1 R. M.Pandey,3 R. L. Mitsuyasu,4 andJ.L.Fahey5
1Department of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
2Department of Microbiology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
3Department of Biostatistics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
4UCLA Center for Clinical AIDS Research and Education, University of California, Los Angeles, CA 90035, USA
5Department of Medicine and Microbiology, University of California, Los Angeles, CA 90095, USA
Correspondence should be addressed to S. Sinha, sanjusinha@hotmail.com
Received 31 August 2011; Accepted 4 January 2012
Academic Editor: Ricardo S. Diaz
Copyright © 2012 S. Sinha et al. Thisis an open access article distributed under theCreativeCommons AttributionLicense, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. The increased use of antiretroviral therapy (ART) has reduced the morbidity and mortality associated with HIV,
adversely leading to the emergence of HIV drug resistance (HIVDR). In this study we aim to evaluate the prevalence of HIVDR
mutations in ART-naive HIV-1 infected patients from northern India. Design. Analysis was performed using Viroseq genotyping
system based on sequencing of entire protease and two-thirds of the Reverse Transcriptase (RT) region of pol gene. Results.S ev e n ty
three chronic HIV-1 infected ART na¨ ıve patients eligible for ﬁrst line ART were enrolled from April 2006 to August 2008. In 68
patients DNA was successfully ampliﬁed and sequencing was done. 97% of HIV-1 strains belonged to subtype C, and one each to
subtype A1 and subtype B. The overall prevalence of primary DRMs was 2.9% [2/68, 95% conﬁdence interval (CI), 0.3%–10.2%].
One patient had a major RT mutation M184V, known to confer resistance to lamivudine, and another had a major protease
inhibitor (PI) mutation D30N that imparts resistance to nelﬁnavir. Conclusion. Our study shows that primary HIVDR mutations
have a prevalence of 2.9% among ART-naive chronic HIV-1 infected individuals.
1.Introduction
The national antiretroviral therapy (ART) program in India
for treatment of human immunodeﬁciency virus (HIV) and
acquired immune deﬁciency syndrome (AIDS) was started
by National AIDS Control Organization (NACO), Ministry
of Health and Family Welfare, Government of India, in April
2004. By the end of November 2009, more than 2, 50,000
patients infected with HIV had received ART under the
program [1]. As per the latest report by Joint United Nations
programe on HIV/AIDS (UNAIDS), prevalence of HIV in
India is estimated to be 0.31%, that translates to approx-
imately 2.31 million persons living with HIV/AIDS [2].
The current standard ﬁrst-line treatment for HIV in India
consists of two nucleoside reverse transcriptase inhibitors
(NRTIs), zidovudine or stavudine plus lamivudine, and
one nonnucleoside reverse transcriptase inhibitor (NNRTI),
nevirapine or efavirenz. Regimens with protease inhibitors
(PIs) are available as second-line treatment options upon
failure of the ﬁrst-line ART under the national program. As
per the time trends for evolution of primary HIVDR sug-
g e s t e db yG r a n te ta l ., it can be expected that the prevalence
of drug resistance mutations (DRMs) may soon increase
in India [3, 4]. The widespread use of ART has resulted
in an increased prevalence of drug-resistant HIV strains,
ranging from 10% to 20% among drug-naive patients in
other countries [5–7]. The emergence HIVDR is inevitable,
given the high replication and mutation rates of HIV, and the
necessity for lifelong ART, which may not always be available
to HIV-infected individuals in resource-limited settings, due2 AIDS Research and Treatment
to multitude of practical and logistic barriers. The genetic
diversity of HIV-1 originates from rapid viral replication in
infected individuals with a high rate of incorrect nucleotide
substitutionsintheviralgenome.DRMsresultfromselective
pressureduring viralreplication, especiallyin the presenceof
subtherapeutic levels of ART [8, 9].
Due to the predominance of subtype C in India, and
limiteddataonnonsubtypeBcirculatingHIVstrains,studies
toassessbaseline,pretreatmentDRMsinindividualsinfected
with HIV-1 clade C are warranted [10]. It has also been
established that patients who started their ﬁrst-line ART
regimen determined by baseline HIV genotypic testing have
greaterandlongerlastingHIVviralsuppressionwiththerapy
than those without HIVDR genotyping [11, 12]. Given the
high cost and handling expertise for the genotyping assay
in a resource-limited setting, prevalence studies are helpful
in providing trends about HIV subtypes and the pattern of
DRMs from a region. A recent study done at Mumbai in
Western India by Deshpande et al. [13] included about 50
ART na¨ ıve HIV patients and showed 9.6% prevalence of
DRMs. Similarly, another study done by Thorat et al. [14],
from Kakinada in southern India, has shown the prevalence
of DRMs to be <5% in HIV-infected ART-na¨ ıve population.
The present study discusses the prevalence of DRMs
existing in treatment-na¨ ıve HIV-1-infected individuals from
northern India and assesses the subtypes prevalent in these
individuals.
2.MaterialandMethods
2.1. Patient Population. All HIV-infected patients visiting
Integrated Counseling and Testing centre (ICTC) and ART
clinic at All India Institute of Medical Sciences (AIIMS),
New Delhi, were screened for eligibility. They had been
conﬁrmed for HIV-1 seropositivity by three sets of Enzyme-
linked Immunosorbent Assay (ELISA) according to NACO
guidelines [15, 16]. Detailed treatment history was taken
from all patients. Those who reported no prior exposure
to antiretroviral drugs were considered ART na¨ ıve. Only
adult (>18 years of age) patients with CD4 cell counts
below 200/µL were considered for entry into the study. The
study was approved by AIIMS ethics committee and written
informed consent was taken from all study participants.
Seventy-three chronic HIV-1-infected ART-na¨ ıve individu-
als, who were eligible for ﬁrst-line ART, were enrolled from
April 2006 to August 2008. DNA was successfully ampliﬁed
and sequenced in plasma samples from 68 patients.
2.2. Specimens. Ten milliliters (mL) of whole blood sample
were taken from each patient. Three mL were used for CD4+
T cells count estimation, and the remaining was centrifuged
within 6 hours of collection at 400g for 10 minutes in order
toseparateplasma.Plasmawasdistributedinto1mLaliquots
a n ds t o r e df r o z e na t−70◦C. Fresh aliquots of plasma were
used for HIV-1 RNA quantiﬁcation and HIV-1 genotyping
aspertheWHOandHIVResNet LaboratoryWorking Group
resistance testing guidelines [17].
2.3.ViralLoadTestingandCD4Estimation. Viralloadtesting
was performed using the standard protocol of AMPLICOR
HIV-1 Monitor Test, version 1.5 (Roche Molecular Systems
Inc., Branchburg, NJ, USA). CD4/CD8+ T cell counts were
determined by ﬂow cytometry using BD FACS CALIBUR
(BD Biosciences, Calif, USA).
2.4. HIV-1 Genotyping. HIV-1 genotyping was performed
using the Abbott ViroSeq HIV-1 Genotyping Systems
(Abbott diagnostics, Wiesbaden, Germany) to sequence the
1.8 kb protease-RT region of HIV-1 pol gene as per standard
procedure [17]. RNA extraction was performed on 500
microlitre (µL) of plasma using the guanidine-thiocynate
extraction method. A reverse transcription polymerase chain
reaction (RT-PCR) followed by PCR was carried out to
generate an amplicon of 1.3 kb. The amplicons were puriﬁed
using silica spin columns, and PCR products were run
on 1% agarose gel against 2 mass ladders allowing for
semiquantitation of DNA. For sequencing, DNA was diluted
according the band intensity on agarose gel, and PCR
product bands with DNA >20 nanogram were selected. The
latter were added to a 96-well reaction plate containing
premixed Big Dye sequencing primers A, B, C, F, G, and
H[ 17]. Sequencing was indigenously carried out in the
Department of Microbiology, AIIMS, on the 16 capillary
automated ABI PRISM 3130xl Genetic Analyzer (Applied
Biosystems, Foster City, CA) using data collection software
v3.0 and sequence analysis software v5.3. ViroSeq HIV-
1 Genotyping System Software v2.8 was used to assemble
the chromatographs from the seven primers into a single
project, and to generate a contiguous sequence spanning
the entire protease gene, and up to codon 335 of the
reversetranscriptase(RT)gene.Thisconsensussequencewas
compared to a known reference strain, HXB-2, to identify
points of variance. The sequences were manually edited and
savedinF AST AformatwhichwassubmittedtoStanfordHIV
RT and Protease sequence database [18] to determine the
drug-resistance proﬁle and subtype of each sample. DRMs
were deﬁned according to WHO Surveillance mutation list
2009 proposed by Bennett et al. [19].
2.5. Quality Control. For quality control of HIV-1 geno-
typing, negative, low-positive, and high-positive control
samples were run with every batch. The positive controls
ensuredtheRT-PCRandgenotyping success.Toensuregood
sequence quality, the high-positive control was sequenced
before genotyping the HIV-1 clinical samples, precluding
editing mistakes. Phylogenetic analysis was performed to
check for contamination as per procedures described in the
Los Alamos website (http://www.hiv.lanl.gov/)[ 20].
2.6. Clade Typing and Phylogenetic Tree. HIV-1 subtype was
deﬁned using REGA HIV-1 subtyping tool from Stanford
HIV drug-resistance database (http://hivdb.stanford.edu/)
[18], Worldwide subtype references were obtained from the
Los Alamos HIV database [20]. For phylogenetic study,
nucleotide sequences were aligned using software’s GeneDoc
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programe. Genetic distances at nucleotide and amino acid
level were calculated using MEGA software v4.0. The
neighbor-joining method and kimura two-parameter model
were used for tree construction with reliability estimated
from 1000 bootstrap replicates [21, 22].
2.7. Statistical Analysis. Data was ﬁrst recorded on a
predesigned paper form and subsequently transferred to
Microsoft Excel spreadsheet. All the entries were checked for
possible keyboard error(s) at the entry level. The electronic
data was exported into the STATA software v11, for statistical
analysis. Baseline clinical and biological characters of the
study subjects were summarized as frequency (%) for
the categorical variables; and mean ± standard deviation
(SD) or median {Interquartile range (IQR)} for quantitative
variables. Prevalence of DRMs was computed with 95%
conﬁdence interval (CI).
3. Results
A total of 73 patients were recruited into the study. Geno-
typing was possible in plasma samples from 68 (93%) of the
participants. Five samples failed PCR ampliﬁcation, of which
3hadviralloadbelow1000copies/mL,andfortheremaining
two,reasonswereunknown.Ofthestudyparticipants,91.2%
gave a history of heterosexual exposure, 4.4% had bisexual
behavior, and the rest did not reveal their HIV exposure
history. Subtype C was found to be the most predominant
subtype(97%)in ourpopulation (Table 1 andFigure 1).The
median age of the study group was 35 years (range: 20–55
years). The median CD4 count was 107 cells/µL (range: 49–
157cells/µL), and the median plasma HIV RNA load was
223640 copies/mL (5.34 log10), range: 8264 (4.98 log10)–
750000 (5.75 log10).
Major HIV drug-resistance mutations were isolated from
twoof68patients(2.9%;95%CI,0.3%–10.2%). Onepatient
(1.47%) had RT mutation, M184V that imparts resistance to
NRTIs, lamivudine, and emtricitabine, and another (1.47%)
had a major PI mutation, D30N, conferring resistance to
nelﬁnavir. No NNRTI mutations were observed in our study
(Table 2). Accessory minor PI mutations K20R, M36I, and
H69K were seen in 7.3% (5/68), 97% (66/68), and 49%
(33/68) patients, respectively; L63P, A71E, A71V, I13V, L10V,
K45I, and K45R were observed in one patient each.
4. Discussion
This is the ﬁrst study sponsored by NACO for estimation of
HIVDR mutation in ART-na¨ ıve population from northern
India. Its results reveal overall prevalence of primary HIVDR
to be 2.9% (CI, 0.3%–10.2%) in this region. As per WHO
guidelines, the drug-resistance prevalence in a geographical
area has been categorized into <5%, 5–15% and >15% [23].
This classiﬁcation signiﬁes the level of HIVDR surveillance
programs required for monitoring primary HIVDR. An
earlier study done by Chaturbhuj et al. [24] in 2010 has
shown that the presence of surveillance DRMs in ART-na¨ ıve
HIV-1-infected individuals recruited from Voluntary Centre
Table 1: Baseline clinical and biological characteristics of the 68
study subjects.
Variables Summary,
n = 68
Age(yrs), median (IQR) 35 (30–40)
Gender, n (%):
Male
Female
61 (89.7%)
07 (10.3%)
Median CD4Tcell count, cells/µL (IQR) 107 (49–157)
Median Viral load, log10 copies/mL (IQR) 5.34 (4.98–5.75)
Viral load (log10 copies/mL), n (%):
<4.0
4.0–4.9
≥5.0
2 (2.9%)
14 (20.6%)
52 (76.5%)
Risk exposure, n (%):
Heterosexual (%)
Bisexual (%)
Others/unknown (%)
62 (91.2%)
3 (4.4%)
3 (4.4%)
Other coinfections, n (%) 57 (83.8%)
HIV-1 subtypes, (%):
Subtype C
Subtype A1
Subtype B1
97%
1.5%
1.5%
Values are expressed as number (%) or median (Interquartile range).
for Testing and Counselling (VCTC) was less than the WHO
threshold of 5%. Our data ﬁts in the WHO low zone of
(<5%), suggesting that primary HIV drug resistance is still
under the limits in northern India, nevertheless there is a
need for more data on primary drug resistance in ART na¨ ıve
individuals.
In our study M184V, an RT mutation, which confers
resistance to lamivudine was isolated in one case. Though
this mutation is found most commonly in patients failing
ART, it is rarely seen in ART-na¨ ıve patients as a transmitted
drug-resistance (TDR) mutation [25]. This may be due to
the diminished replicative capacity of the virus carrying this
mutation, which increases the probability of the virus to get
reverted back to the wild type. In earlier studies from India,
M184V was found in two of 128 (1.6%) cases by Deshpande
et al. in 2004 [26], and in one of 40 (2.5%) cases by Lall et al.
2009 [27]. No NNRTI mutations were detected in our study,
whichisconsistentwiththeﬁndingsofDeshpandeetal.[26].
One participant (1.5%) in our study had a major PI
mutation, D30N, in the protease gene. This ﬁnding is close
to that of Hira et al., who have shown a prevalence of 2.5%
for major PI DRMs in ART-na¨ ıve HIV-infected population
in India [28]. However, prevalence of the same has been
reported to be as high as 20% in south India by Balakrishnan
etal.[29],and14.2%byAroraetal.[30]innorthIndia.Since
PI-based regimens are used less frequently in this country
and have been distributed under the national program
only after 2008, the prevalence of major PI mutation in
the population may be assumed to be below 5%, as also
corroborated by Chaturbhuj et al. in 2010 [24]. The possible
reasons for reporting the higher DRMs by a few of the4 AIDS Research and Treatment
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Figure 1: Phylogenetic relationship based on pol gene (1302nt) sequences (shown in red and green color) and global HIV-1 subtype
reference sequences (A1, A2, HXB2, C India, C Zambia, C Ethiopia, C Brazil, D, F, G, H J, and K from Los Alamos HIV Sequence Database).
earlier studies may be the confusion over proper deﬁnitions
of primary and TDR mutations, and nonuniformity between
protocols for HIVDR surveillance until WHO criteria were
published in 2009 [19].
One of the limitations of our study was that the study
was designed and carried out at a time when WHO guide-
lines were not available and patients were tested at the
pretreatment baseline rather than at the time of diagnosis.AIDS Research and Treatment 5
Table 2: Data of two study participants detected with NRTI and PI drug-resistance mutations.
Study ID CD4 count (cells/µL) Viral load (copies/mL) HIV-1 subtype Drug resistance mutations by antiretroviral class∗
NRTI PI
AIIMS 10 157 63721 C M184V —
AIIMS 81 77 >750000 C — D30N
∗Standard single-letter amino acid codes indicate mutations. NRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor.
Hence, some of the mutated HIV strains may have reverted
to the wild type, and we may have underestimated the
prevalence of primary HIVDR [31, 32]. The other reason for
underestimation of mutations could be that the sensitivity of
detectionofminorityspeciesbystandardgenotypicmethods
using population-based sequencing is only about 20% [33].
Another limitation of study is the small sample size, as HIV
genotyping is costly, and limited funding was available for
the study. A third limitation is that all patients may not have
been ART-na¨ ıve, as chronically infected individuals often do
not want to admit to previous treatment [34].
Our observation shows that 97% of the patients were
infected with subtype C of HIV type 1. The subtype C strains
clustered together along with the Indian reference strain
(95IN216068). Previous studies performed in diﬀerent parts
of the country also corroborate the predominance of HIV-1
subtype C strains in India [35, 36]. Interestingly, along with
subtypeC,onestnaineachofsubtypeBandsubtypeA1were
also found in our patient population. Similar ﬁndings have
been reported earlier by Baskar et al. [37], and Gadkari et al.,
respectively [38].
In conclusion, our study reveals that the prevalence of
primary HIV DRMs is 2.9% in northern India, which is
within the WHO threshold limit of <5%. This ﬁnding rein-
forces the national program’s eﬀort in maintaining low level
of primary drug resistance among HIV-infected population.
Due to the limited options for second- and third-line ART in
a resource-constrained setting, baseline HIV genotyping is
required for better patient monitoring and keeping HIVDR
in check. However, until the procedure becomes more
aﬀordable, there is a need for continued surveillance and
further prevalence studies with larger sample sizes to assess
primary drug resistance patterns in the Indian HIV-infected
population.
SequenceData
T h eP Ra n dR Tn u c l e o t i d es e q u e n c e so fs t u d yi s o l a t e s
are available under the accession numbers: HQ453364 to
HQ453394.
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